EUVIMEDOpdag EUVIMED
Übersichtsarbeit

Targeting Nur77 in Fibrosis and Aging: Context‐ and Stage‐Specific Molecular Mechanisms and Therapeutic Strategies

Chenxi Lu iD, Wenxiao Wang, Yahui Jin, Xue Wu iD

Journal of Cellular Physiology · 2026-11 · 241 (11)

DOI: 10.1002/jcp.70246 ↗

At a glance

Übersichtsarbeit in Journal of Cellular Physiology, published online on 2026-11-04. Written by Chenxi Lu and 3 co-authors. Institution: Yan'an Medical College, Yan'an University, Yan'an, Shaanxi, China. Major MEDLINE topics: Nuclear Receptor Subfamily 4, Group A, Member 1, Aging, Fibrosis. 146 references. Funded by: National Natural Science Foundation of China, Natural Science Basic Research Program of Shaanxi Province, Xi'an Science and Technology Bureau Projects.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Fibrosis represents the end‐stage manifestation of numerous chronic diseases, characterized by persistent inflammatory cell infiltration, fibroblast‐to‐myofibroblast transition, and excessive extracellular matrix (ECM) deposition. This pathological process significantly contributes to the progression of chronic conditions and age‐related organ dysfunction. Nur77 (also designated as NR4A1, NGFI‐B, or TR3), an immediate‐early response gene product, is rapidly activated by diverse stimuli including growth factors, inflammatory signals, cytokines, and cellular stress. Emerging evidence establishes Nur77 as a critical regulator of fibroblast dynamics, governing their activation, proliferation, migration, and ECM production. The functional significance of Nur77 in fibrotic pathogenesis has been demonstrated across multiple organ systems,particularly in the heart, liver, lungs, and kidneys, positioning it as a promising therapeutic target for antifibrotic interventions. This review systematically examines the mechanistic basis of Nur77 involvement in fibrosis, detailing its regulatory effects on immune and stromal cells through multiple signaling pathways. We further analyze its participation in fibrosis‐associated pathological processes and specific diseases, as well as explore the interconnection between aging and fibrosis, and assess the therapeutic potential of Nur77. Collectively, this synthesis underscores Nur77 as an emerging molecular target with substantial promise for combating fibrosis and aging‐related diseases.

Subjects

MeSH terms (MEDLINE)

Nuclear Receptor Subfamily 4, Group A, Member 1AgingFibrosisHumansAnimalsSignal TransductionExtracellular MatrixFibroblasts

Author keywords

Nur77agingfibrosisorgan injury

Substances

Nuclear Receptor Subfamily 4, Group A, Member 1NR4A1 protein, human

Authors and institutions

  • Yan'an Medical College, Yan'an University, Yan'an, Shaanxi, China.

ORCID profiles: Chenxi Lu, Xue Wu

Funding

  • National Natural Science Foundation of China
  • Natural Science Basic Research Program of Shaanxi Province
  • Xi'an Science and Technology Bureau Projects
  • Shaanxi Provincial Department of Education
  • Doctoral Research Start-up Foundation from Yan'an University
  • Education Department of Shaanxi Province

Cite

APA

Lu, C., Wang, W., Jin, Y., & Wu, X. (2026). Targeting Nur77 in Fibrosis and Aging: Context‐ and Stage‐Specific Molecular Mechanisms and Therapeutic Strategies. Journal of Cellular Physiology, 241(11). https://doi.org/10.1002/jcp.70246

Vancouver

Lu C, Wang W, Jin Y, Wu X. Targeting Nur77 in Fibrosis and Aging: Context‐ and Stage‐Specific Molecular Mechanisms and Therapeutic Strategies. Journal of Cellular Physiology. 2026;241(11). doi:10.1002/jcp.70246

BibTeX
@article{Lu2026,
  author = {Lu, Chenxi and Wang, Wenxiao and Jin, Yahui and Wu, Xue},
  title = {Targeting Nur77 in Fibrosis and Aging: Context‐ and Stage‐Specific Molecular Mechanisms and Therapeutic Strategies},
  journal = {Journal of Cellular Physiology},
  year = {2026},
  volume = {241},
  number = {11},
  doi = {10.1002/jcp.70246}
}
Start for free →